Spinal fluid T-DXd for HER2 breast cancer spread to the brain
Tests spinal fluid T-DXd in HER2 breast cancer reaching the brain.
Key facts
- Who runs it
- Fudan University
- Where
- China2 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 139 people, planned
- Started
- 12 May 2025
- Expected to end
- 28 Jun 2027
- Type of study
- Interventional, 10 groups
- Treatments tested
- T-DXd
- Record updated
- 26 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with HER2-expressing advanced or spread breast cancer that has reached the brain lining (leptomeningeal metastasis) and/or the brain. T-DXd is given into the spinal fluid together with treatment through the blood.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Advanced or metastatic breast cancer with leptomeningeal metastasis. People with active brain metastases only need at least one brain tumour that can be measured on scans (RANO-BM criteria). Some groups need cancer in the brain or brain lining that is growing.
- Earlier treatment
- No radiotherapy, chemotherapy, targeted therapy, immunotherapy, endocrine therapy or surgery within 2 weeks before joining (or within 5 half-lives of the earlier therapy, whichever is shorter). Side effects of earlier treatment must have eased to Grade 1 or lower. Some groups are for people who already had T-DXd, others for people who never had it.
- Biomarker or test result
- HER2-expressing breast cancer: HER2-positive or HER2-low (IHC 1+ or 2+/ISH-), depending on the group.
Main reasons for not taking part
- Another cancer in the past 5 years, except some early or skin cancers that were treated and gone
- Past lung inflammation (ILD/pneumonitis) needing steroids, or current or suspected ILD/pneumonitis
- Known HIV infection, active hepatitis B or C, or uncontrolled infections needing IV medicines
- Active autoimmune disease, or immunosuppressants or systemic steroids over 10 mg/day prednisone equivalent within 2 weeks
- Pregnant or breastfeeding women, or people unwilling or unable to use effective birth control
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Age ≥18 years, regardless of gender
- HER2-expressing advanced or metastatic breast cancer
- Leptomeningeal metastasis
- Subjects with active brain metastases only must have at least one intracranially measurable lesion (RANO-BM criteria)
- Adequate organ and bone marrow function
- No radiotherapy, chemotherapy, targeted therapy, immunotherapy, endocrine therapy, or surgery within 2 weeks prior to enrollment (or within 5 half-lives of prior therapy, whichever is shorter)
- All prior treatment-related toxicities must have resolved to ≤Grade 1
Who cannot take part
- Uncontrolled concurrent illnesses including, but not limited to: persistent or active infections, uncontrolled or clinically significant cardiovascular diseases, severe chronic gastrointestinal disorders with diarrhea, or psychiatric/social conditions that may compromise compliance with study requirements, significantly increase AE risks, or impair the subject's ability to provide written informed consent
- Use of immunosuppressants or systemic corticosteroids (>10 mg/day prednisone equivalent) for immunosuppression within 2 weeks prior to first dose (excluding intranasal/inhaled corticosteroids)
- Diagnosis of other malignancies within the past 5 years, except for cured carcinoma in situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin, other in situ carcinomas, or papillary thyroid carcinoma
- History of (non-infectious) ILD/non-infectious pneumonitis requiring steroid therapy, current ILD/non-infectious pneumonitis, or suspected ILD/non-infectious pneumonitis that cannot be ruled out by imaging during screening
- Any active autoimmune disease or history of autoimmune disease with potential recurrence
- Uncontrolled infections requiring IV antibiotics, antivirals, or antifungals
- Active primary immunodeficiency, known HIV infection, active HBV (HBsAg+ with HBV DNA ≥500 IU/mL) or HCV infection. HCV antibody-positive subjects are eligible only if PCR confirms HCV RNA negativity
- Radiographic evidence of tumor encasement/invasion of major blood vessels, or investigator-determined high risk of fatal hemorrhage due to probable vascular invasion during treatment
- Any other condition deemed by investigators to potentially affect trial conduct or outcome interpretation
- Clinically significant pulmonary comorbidities
- Pregnant/lactating women, or subjects of reproductive potential unwilling/unable to use effective contraception
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Multiple trials confirm systemic T-DXd efficacy in HER2+ breast cancer with leptomeningeal/brain metastases, yet median LM survival remains 3-4 months, highlighting unmet needs. While systemic therapies improve survival, intracranial disease control remains limited due to poor BBB penetration. Preclinical data show no detectable T-DXd/DXd in CSF, though intrathecal trastuzumab demonstrates preliminary safety/efficacy in HER2+ LM.
Read full original descriptionShow less
This study evaluates intrathecal/intra-Ommaya T-DXd plus systemic therapy in active HER2+ meningeal/brain metastases, assessing safety, intracranial efficacy, and CSF/peripheral blood T-DXd distribution to clarify BBB penetration potential. Findings may guide novel therapeutic strategies for this high-need population.
The 10 groups in the trial
- Phase I/Arm A(Intrathecal Dose-Escalation Phase)Treatment being tested
Population : T-DXd-naïve subjects with leptomeningeal metastases (LM), with or without concurrent brain metastases (BM). Cycle 1 : Intrathecal (IT) T-DXd monotherapy to assess cerebrospinal fluid (CSF) and systemic pharmacokinetics (PK). Cycles 2+ : IT T-DXd combined with intravenous (IV) T-DXd in a dose-escalation design to determine the maximum tolerated dose (MTD) . DLT Evaluation : The first two cycles serve as the dose-limiting toxicity (DLT) observation window . Endpoint : The recommended Phase 2 dose (RP2D) will be determined by investigator assessment
Treatment: T-DXd
- Phase I/Arm B(Systemic-to-Intrathecal Transition Phase)Treatment being tested
Population : T-DXd-naïve subjects with LM ± BM. Cycle 1 : IV T-DXd monotherapy to characterize CSF and systemic PK profiles. Cycles 2+ : IT administration of the RP2D of T-DXd combined with IV therapy
Treatment: T-DXd
- Phase II/Arm ATreatment being tested
HER2-positive advanced breast cancer with progressive leptomeningeal and/or brain metastases after prior T-DXd therapy
Treatment: T-DXd
- Phase II/Arm BTreatment being tested
HER2-low (IHC 1+ or 2+/ISH-) advanced breast cancer with progressive leptomeningeal and/or brain metastases after prior T-DXd therapy
Treatment: T-DXd
- Phase II/Arm CTreatment being tested
HER2-positive advanced breast cancer with progressive brain metastases (without leptomeningeal involvement) after prior T-DXd therapy
Treatment: T-DXd
- Phase II/Arm DTreatment being tested
HER2-low advanced breast cancer with progressive brain metastases (without leptomeningeal involvement) after prior T-DXd therapy
Treatment: T-DXd
- Phase II/Arm ETreatment being tested
T-DXd-naïve HER2-positive advanced breast cancer with progressive leptomeningeal and/or brain metastases
Treatment: T-DXd
- Phase II/Arm FTreatment being tested
T-DXd-naïve HER2-low advanced breast cancer with progressive leptomeningeal and/or brain metastases
Treatment: T-DXd
- Phase II/Arm GTreatment being tested
T-DXd-naïve HER2-positive advanced breast cancer with progressive brain metastases (without leptomeningeal involvement)
Treatment: T-DXd
- Phase II/Arm HTreatment being tested
T-DXd-naïve HER2-low advanced breast cancer with progressive brain metastases (without leptomeningeal involvement)
Treatment: T-DXd
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluating Safety and Efficacy of INtrathecal or Ommaya ReserVoir Administration of T-DXd in Patients With HER2-Expressing Breast Cancer With Active Leptomeningeal and/or Brain Metastases Based on Systemic Therapy: Phase I/II Study
- Plain-language title
- Spinal fluid T-DXd for HER2 breast cancer spread to the brainGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 26 October 2026